wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q50105551-320F982E-D128-4BF5-AD8B-67047CF75981
Q50105551-320F982E-D128-4BF5-AD8B-67047CF75981
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50105551-320F982E-D128-4BF5-AD8B-67047CF75981
Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.
P2860
Q50105551-320F982E-D128-4BF5-AD8B-67047CF75981
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50105551-320F982E-D128-4BF5-AD8B-67047CF75981
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1f32b72ffb14472bc725e974150398147a3d3bdf
P2860
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al